Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

HSPG2 anticorps

Cet anticorps anti-HSPG2 est un anticorps Rat Monoclonal détectant HSPG2 dans IF, IHC (p) et FACS. Adapté pour Humain, Souris, Boeuf (Vache), Poisson, Singe et Porc.
N° du produit ABIN3023902

Aperçu rapide pour HSPG2 anticorps (ABIN3023902)

Antigène

Voir toutes HSPG2 Anticorps
HSPG2 (Heparan Sulfate Proteoglycan 2 (HSPG2))

Reactivité

  • 30
  • 19
  • 7
  • 4
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
Humain, Souris, Boeuf (Vache), Poisson, Singe, Porc

Hôte

  • 23
  • 10
  • 4
Rat

Clonalité

  • 24
  • 13
Monoclonal

Conjugué

  • 27
  • 4
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp HSPG2 est non-conjugé

Application

  • 24
  • 21
  • 13
  • 12
  • 7
  • 5
  • 5
  • 5
  • 4
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS)

Clone

A7L6
  • Attributs du produit

    This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.

    Purification

    Protein G affinity chromatography

    Immunogène

    A murine EHS laminin preparation was used as the immunogen for the Perlecan antibody.

    Isotype

    IgG2a kappa
  • Indications d'application

    Optimal dilution of the Perlecan antibody should be determined by the researcher.

    1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min
    2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2)

    Restrictions

    For Research Use only
  • Concentration

    1 mg/mL

    Buffer

    1 mg/mL in 1X PBS, BSA free, sodium azide free

    Agent conservateur

    Azide free

    Stock

    4 °C,-20 °C

    Stockage commentaire

    Store the Perlecan antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
  • Antigène

    HSPG2 (Heparan Sulfate Proteoglycan 2 (HSPG2))

    Autre désignation

    Perlecan (HSPG)

    Sujet

    This mAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.

    Pathways

    Glycosaminoglycan Metabolic Process, Lipid Metabolism
Vous êtes ici:
Chat with us!